Pathology
Ovarian cancer is a malignant tumor affecting the ovaries, organs of the female reproductive system responsible for producing oocytes and secreting female sex hormones such as estrogen and progesterone.
Ovarian cancer arises from the uncontrolled proliferation of ovarian cells. In most cases, it originates from epithelial cells lining the ovary, although it may also arise, more rarely, from germ cells or sex cord–stromal cells.
It is often an insidious disease because in its early stages it may not produce specific symptoms; for this reason, it is frequently diagnosed at an advanced stage. However, when detected early, ovarian cancer can be treated more effectively.
The Numbers in Italy
In 2024, according to the AIRTUM (Italian Association of Cancer Registries), ovarian cancer in Italy recorded approximately 5,423 new diagnoses.
Types
Ovarian cancer can develop from different cellular components of the ovary.
Epithelial Tumors
These are the most common (about 90% of cases) and originate from the ovarian surface epithelium:
- Type I: low-grade serous, mucinous, endometrioid, and clear cell tumors
- Type II: high-grade serous tumors, which are the most frequent and clinically aggressive
Borderline Tumors
Tumors with low malignant potential, often diagnosed at early stages and in younger patients. They generally have a favorable prognosis and can often be managed with conservative surgery.
Stromal or Sex Cord Tumors
Rare tumors arising from the ovarian connective tissue and capable of hormone production. They include granulosa cell tumors, thecoma-fibroma tumors, and Sertoli–Leydig cell tumors.
Germ Cell Tumors
Rare (approximately 5% of cases), originating from oocyte precursor cells. They occur most commonly in women under 30 years of age. Main types include teratomas, dysgerminomas, yolk sac tumors, and choriocarcinomas.
Symptoms
Ovarian cIn early stages, ovarian cancer often causes no specific symptoms, making early diagnosis difficult. When present, symptoms may include:
- Abdominal bloating or persistent feeling of fullness (meteorism)
- Increased urinary frequency
- Abdominal or pelvic pain
- Vaginal bleeding
- Constipation or diarrhea
- Unexplained fatigue
- Nausea or loss of appetite (more common in advanced stages)
- Early satiety (feeling full shortly after starting a meal)
If these symptoms occur together or persist over time, gynecological evaluation is recommended.
Risk Factors
The main risk factors for ovarian cancer include:
- Early menarche or late menopause
- First pregnancy after the age of 35
- Pelvic inflammatory disease
- Nulliparity (having no children)
- Family history of ovarian or breast cancer
- Genetic mutations (BRCA1/BRCA2, Lynch syndrome)
- Endometriosis
- Polycystic ovary syndrome (PCOS)
Protective factors include breastfeeding, younger age at first pregnancy (<25 years), and the use of oral contraceptives.
Diagnosis and Examination
To date, there are no diagnostic procedures with sufficient sensitivity and specificity for effective early detection; therefore, there is no established screening program for malignant ovarian cancer.
In cases of clinical suspicion, second-level investigations are usually performed, including:
- Serum tumor markers (CA-125, CA19-9, CA15-3, CEA, alpha-fetoprotein)
- Level 2 transvaginal ultrasound performed by an experienced operator
- Contrast-enhanced CT scan of the chest, abdomen, and pelvis
If further evaluation is required, pelvic MRI and/or total-body PET scanning may also be performed.
A definitive diagnosis is established only through histological examination of surgical specimens.
Therapies
The Ovarian Cancer Center is a highly specialized referral unit offering a multidisciplinary approach to patients with ovarian cancer. Treatment is individualized and includes both surgical and medical (chemotherapy) strategies.
In selected cases, particularly in patients who wish to preserve fertility, fertility-sparing surgery may be considered. This involves removal of the tumor while preserving part of the ovary and/or uterus, when oncologically safe, to maintain future fertility potential. The decision is made by a multidisciplinary team based on tumor stage, histological type, and oncological safety.
Medical treatment, administered before or after surgery, includes systemic chemotherapy and maintenance therapies. These may involve targeted biological agents such as monoclonal antibodies and oral therapies, including PARP inhibitors. The choice of therapy is guided by molecular and genetic profiling of the tumor.
Early Stage Ovarian Cancer
When the disease is limited to one or both ovaries, surgical management may include:
- Bilateral hysterectomy with bilateral salpingo-oophorectomy (BSO): removal of the uterus, both ovaries, and fallopian tubes in order to eliminate all potential sites of disease spread or recurrence within the female reproductive tract.
- Peritoneal staging (e.g., omentectomy): removal of the omentum, an abdominal fatty tissue that may harbor occult metastatic disease.
- Retroperitoneal staging (pelvic and para-aortic lymphadenectomy): removal of lymph nodes in the pelvic and para-aortic regions to assess whether the disease has spread beyond the ovaries.
Surgical access
- Laparotomy: open surgical approach involving a large abdominal incision, allowing direct access to pelvic and abdominal organs.
- Operative laparoscopy: minimally invasive surgical technique performed through small incisions (typically ~5 mm), associated with reduced postoperative pain, shorter hospital stay, and faster recovery.
Advanced Ovarian Cancer
When the disease extends beyond the ovaries, the diagnostic and therapeutic pathway involves several steps:
- Diagnostic Laparoscopy: performed to directly assess intra-abdominal tumor spread, avoiding reliance solely on radiological imaging. It allows visualization of tumor distribution and enables biopsy sampling for immediate histological examination, supporting intraoperative diagnostic confirmation.
- Cytoreducibility Assessment: evaluation of the feasibility of optimal debulking using scoring systems such as the Predictive Index Value (PIV) or Fagotti score. This determines the likelihood of achieving optimal cytoreduction (complete macroscopic tumor removal or residual disease < 1 cm).
- If the score is favorable, Primary Debulking Surgery (PDS) is performed in the same operative session. Cytoreductive surgery involves removal of all macroscopically visible tumor, including the uterus, ovaries, omentum, and pathologically enlarged lymph nodes, as well as any other involved tissues or organs.
- If the tumor is not considered resectable, targeted biopsies are performed to define the histological, molecular, and genetic profile of the disease. Patients are then started on neoadjuvant chemotherapy to reduce tumor burden. After approximately 3 cycles of chemotherapy, surgery is typically reassessed and scheduled if operability improves.
Ongoing Support
At the Candiolo Cancer Institute, patients receive continuous support before, during, and after treatment.
Our multidisciplinary teams accompany each patient throughout the entire diagnostic, therapeutic, and recovery pathway, providing personalized care and support at every stage.
Management of Emergencies and Side Effects
Cancer patients often require ongoing medical support throughout their treatment journey. When symptoms arise, whether related to the disease itself or to treatment-related side effects, it is important that they can promptly access specialist advice through a dedicated fast-track pathway.
For this reason, the Candiolo Cancer Institute provides a dedicated support service Monday through Friday, from 8:00 a.m. to 5:00 p.m. Patients can contact the Oncology Day Hospital Secretariat at +39 011 993 3775 to request an urgent consultation. Following the request, the patient is promptly contacted by their specialist physician for assessment and guidance.
Psychological Support
A cancer diagnosis affects not only physical health but also emotional and psychological well-being. Coping with cancer is often a profoundly challenging experience that can give rise to feelings of anxiety, fear, anger, and depression.
At the Candiolo Cancer Institute, psychological support is an integral part of the care pathway. Alongside advanced medical treatments, patients have access to qualified psycho-oncological support designed to help them navigate the emotional challenges associated with diagnosis, treatment, and recovery.
Patients may also participate in psychological support groups, providing an opportunity to share experiences, receive mutual support, and connect with others who are facing or have faced similar challenges.
Direct Access to Specialists
To ensure timely support and provide prompt answers to questions or concerns, the Candiolo Cancer Institute offers a dedicated assistance service for all patients.
From Monday through Friday, between 8:00 a.m. and 5:00 p.m., patients can contact the Oncology Day Hospital Secretariat at +39 011 993 3775 to request an urgent consultation.
Patients are promptly connected with their specialist physician, ensuring rapid access to expert advice, clear information, and immediate support when needed.
Supportive and Palliative Care
Cancer patients often have complex needs that extend beyond the treatment of the disease itself and require comprehensive, multidisciplinary care.
At the Candiolo Cancer Institute, patients who need additional support have access to specialists from a range of disciplines, ensuring personalized management of cancer-related symptoms and associated conditions. Services may include nutritional counseling, physical rehabilitation, pain management, and support for other medical needs that may arise during the course of treatment and recovery.
The goal is to improve quality of life, promote overall well-being, and provide comprehensive care tailored to each patient’s individual needs.
Social Work Services
The Social Work Service at the Candiolo Cancer Institute provides information, guidance, and support to patients and their families regarding access to community services and the welfare and social security benefits available under current legislation.
During dedicated consultations, social workers assist with matters such as disability recognition, access to aids and prosthetic devices, employment-related benefits and leave, and other social support services.
The service is available on Wednesdays and Fridays from 9:00 a.m. to 1:00 p.m. and can be contacted at +39 011 993 3059.
Follow-up
Once treatment has been completed, patients enter the follow-up phase, during which regular clinical visits and diagnostic examinations are performed to monitor treatment outcomes, assess any side effects, and evaluate functional recovery.
Follow-up appointments play a crucial role in the early detection of any disease recurrence, allowing timely intervention when necessary. They also provide an important opportunity for patients to discuss concerns, ask questions, and receive ongoing guidance from their specialist physician.
Follow-up visits are scheduled by the patient’s specialist, who evaluates the patient’s overall health status and reviews the results of any required tests and examinations.
Multi Disciplinary Team
Every cancer requires a multidisciplinary approach at all stages of disease management. At the Candiolo Cancer Institute, this is provided by a team of specialists from various clinical and surgical departments, known as the GIC, Interdisciplinary Care Group (or MDT). The GIC ensures that each patient is supported throughout the diagnostic and therapeutic process, including arranging and coordinating examinations and maintaining communication with the patient and their family.
Clinical Divisions
The diagnostic and therapeutic pathway of ovarian cancers at the Candiolo Cancer Institute involves several clinical divisions, including:
- Ovarian Cancer Center
- Gynecology Oncology and Hereditary Tumors
- Medical Oncology
- Anesthesia and Resuscitation
- Nuclear Medicine
- Radiotherapy
- Radiodiagnostics
- Anatomical Pathology
Clinical Studies
Researchers at the Candiolo Cancer Institute are currently involved in numerous national and international projects on gynecological cancers.
Major studies include clinical, translational, and molecular research. In addition, several experimental clinical trials are ongoing, investigating new chemotherapy agents, immunotherapy approaches, and experimental surgical techniques such as hyperthermic intraperitoneal chemotherapy (HIPEC).
Why Choose Us
At Candiolo Cancer Institute, every patient with esophageal cancer is treated in a highly specialized manner, thanks to the synergistic work of the dedicated Interdisciplinary Care Group (GIC) .
Clinical Experience and Tailored Approach
Thanks to the large number of liver cancer cases treated each year, the Candiolo Cancer Institute is a national reference center for the care of this disease. This extensive experience allows us to manage even the most complex cases, always using a personalized approach, tailored to the clinical and individual profile of each patient.
Imaging Technologies and Advanced Diagnostics
Establishing a treatment plan always begins with an accurate and timely diagnosis. Patients have access to state-of-the-art imaging technologies, such as ultrasound, contrast-enhanced CT, MRI, and cholangio-RM, which are critical for accurately assessing the extent of the tumor.
Advanced laboratory tests, including molecular analyses, are also available to help define biological features of the disease and guide treatment choices.
Minimally Invasive Surgical Techniques and Multidisciplinarity
When appropriate, surgeries are performed using minimally invasive, laparoscopic or robotic techniques. These approaches involve the use of camera-equipped instruments introduced into the abdomen through small incisions, thus reducing surgical trauma. Benefits to the patient include shorter hospital stay times, faster recovery, and lower risk of complications compared with traditional open surgery.
Clinical Research and Access to Trials
As an IRCCS (Scientific Institute for Research, Hospitalization, and Healthcare), the Candiolo Cancer Institute combines clinical care with a strong focues on scientific research. Patients can be considered for participation in active clinical trials, offering access to innovative therapies not yet available in standard practice. This integration of care and research is a distinctive strength that translates into tangible benefits for patients.
Care and Support Every Step of the Way
The Interdisciplinary Care Group (GIC or MDT) supports the patient at every stage: from diagnosis, through treatment, to follow-up. Special attention is paid to nutritional support, psychological health and reintegration into daily life. The organization of checkups, examinations, and treatment is designed to ensure continuity, serenity, and a humane, caring approach to each patient’s needs.
